Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed

Exclusion Criteria

• •Patient with baseline SBP \< 100 mmHg
• •Patient with HR\>120 beats/minute
• •Patients with severe or valvular heart disease
• •Patients with an acute coronary syndrome
• •Patients with a creatinine clearance \< 30 ml/min
• •Patients with class IV congestive heart failure
• •Patients with platelet count \< 100,000 per cc3
• •Patients with hemoglobin \< 10g/dl
• •Patient with INR \> 1.5
• •Patients with positive pregnancy test - women between 21 and 60 years of age
• •Patients with known or suspected allergy to study drug or study drug components, including allergy to soybeans, soy products, eggs, or egg products
• •Patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia
• •Patients with contraindications to the use of IV nitroprusside
• •Patients with diagnosed or suspected intra-cardiac or systemic arteriovenous shunts
• •Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 3 months of randomization.
• •Other medical conditions that, in the opinion of the investigator, preclude participation in the study